Search research articles
Contact Us
Filters
Showing results (61-70 of 90) with videos related to
Page
of 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 17, 2001
Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results
O S Breathnach, B Freidlin, B Conley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 1995
Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group
P A Bunn, J Crowley, K Kelly, et al.
British Journal of Cancer
|
April 22, 2015
A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas
Z Eroglu, H A Tawbi, J Hu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 3, 2020
Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials
M Chalabi, A Cardona, D R Nagarkar, et al.
The Cancer Journal From Scientific American
|
April 3, 1999
A phase II evaluation of all-trans-retinoic acid plus interferon alfa-2a in stage IV melanoma: a Southwest Oncology Group study
V K Sondak, P Y Liu, L E Flaherty, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
May 23, 2002
Quality of life in advanced non-small-cell lung cancer: results of a Southwest Oncology Group randomized trial
C M Moinpour, B Lyons, P K Grevstad, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
March 1, 1996
Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide
P J Hesketh, D R Gandara, A M Hesketh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 1995
Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study
K Kelly, J J Crowley, P A Bunn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 1989
GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis
P J Hesketh, W K Murphy, E P Lester, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 1993
Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group
D R Gandara, J Crowley, R B Livingston, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 90) with videos related to
Sort By:
Page
of 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 17, 2001
Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results
O S Breathnach, B Freidlin, B Conley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 1995
Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group
P A Bunn, J Crowley, K Kelly, et al.
British Journal of Cancer
|
April 22, 2015
A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas
Z Eroglu, H A Tawbi, J Hu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 3, 2020
Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials
M Chalabi, A Cardona, D R Nagarkar, et al.
The Cancer Journal From Scientific American
|
April 3, 1999
A phase II evaluation of all-trans-retinoic acid plus interferon alfa-2a in stage IV melanoma: a Southwest Oncology Group study
V K Sondak, P Y Liu, L E Flaherty, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
May 23, 2002
Quality of life in advanced non-small-cell lung cancer: results of a Southwest Oncology Group randomized trial
C M Moinpour, B Lyons, P K Grevstad, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
March 1, 1996
Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide
P J Hesketh, D R Gandara, A M Hesketh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 1995
Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study
K Kelly, J J Crowley, P A Bunn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 1989
GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis
P J Hesketh, W K Murphy, E P Lester, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 1993
Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group
D R Gandara, J Crowley, R B Livingston, et al.
Page
of 9